[go: up one dir, main page]

UY40783A - LYMPHOTOXIN BETA RECEPTOR AGONIST BINDING PROTEINS - Google Patents

LYMPHOTOXIN BETA RECEPTOR AGONIST BINDING PROTEINS

Info

Publication number
UY40783A
UY40783A UY0001040783A UY40783A UY40783A UY 40783 A UY40783 A UY 40783A UY 0001040783 A UY0001040783 A UY 0001040783A UY 40783 A UY40783 A UY 40783A UY 40783 A UY40783 A UY 40783A
Authority
UY
Uruguay
Prior art keywords
binding proteins
beta receptor
lymphotoxin beta
receptor agonist
ltßr
Prior art date
Application number
UY0001040783A
Other languages
Spanish (es)
Inventor
Jun Zhang
Danyang Gong
Nevin Foltz Ian
Rajkumar Noubade
Fernando Garces
Benjamin Case Ryan
Yu WANG Hong
Elaine Tinberg Christine
LAI Chin-Wen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY40783A publication Critical patent/UY40783A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen proteínas de unión a LTßR que interaccionan con un agonista del receptor de linfotoxina beta (LTßR), así como métodos de fabricación y uso de tales proteínas de unión a LTßR. También se describen métodos de tratamiento de un sujeto que tiene un tumor sólido que implican administrar una cantidad farmacéuticamente efectiva de la proteína de unión a LTßR.LTßR-binding proteins that interact with a lymphotoxin beta receptor (LTßR) agonist are described, as well as methods for manufacturing and using such LTßR-binding proteins. Treatment methods for a subject with a solid tumor involving the administration of a pharmaceutically effective amount of the LTßR-binding protein are also described.

UY0001040783A 2023-06-12 2024-06-11 LYMPHOTOXIN BETA RECEPTOR AGONIST BINDING PROTEINS UY40783A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363472565P 2023-06-12 2023-06-12

Publications (1)

Publication Number Publication Date
UY40783A true UY40783A (en) 2024-12-31

Family

ID=91899198

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040783A UY40783A (en) 2023-06-12 2024-06-11 LYMPHOTOXIN BETA RECEPTOR AGONIST BINDING PROTEINS

Country Status (7)

Country Link
CN (1) CN121399157A (en)
AR (1) AR132931A1 (en)
AU (1) AU2024305352A1 (en)
IL (1) IL325097A (en)
TW (1) TW202506733A (en)
UY (1) UY40783A (en)
WO (1) WO2024258870A2 (en)

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DK0463151T3 (en) 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
JP4215172B2 (en) 1996-12-03 2009-01-28 アムジェン フレモント インク． Transgenic mammal having human Ig locus comprising a plurality of V {lower H} and V {lower κ} regions, and antibodies produced therefrom
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
JP5138867B2 (en) 2002-08-01 2013-02-06 イミューノメディクス、インコーポレイテッド α-fetoprotein Immu31 antibody and fusion protein and method of use thereof
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
BRPI0412885A (en) 2003-07-18 2006-10-03 Amgen Inc polypeptides, specific binding agents, nucleic acid molecules and isolated cell lines, host cells, compositions and antigen binding domain or antibody and methods of treating cancer and solid tumor in a patient, detecting growth factor level hepatocyte (hgf) in a sample, obtaining antibody and inhibiting hgf binding to met and decreasing or preventing the binding of any of the hepatocyte growth factor (hgf) -specific binding agents
WO2007005612A2 (en) 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
ES2712942T3 (en) 2006-03-10 2019-05-16 Wyeth Llc Anti-5T4 antibodies and uses thereof
MX363905B (en) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Single-chain multivalent binding proteins with effector function.
JP5209702B2 (en) 2007-04-17 2013-06-12 イムクローン・リミテッド・ライアビリティ・カンパニー PDGFRβ specific inhibitor
AU2008275985B2 (en) 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
PT2222706E (en) 2007-12-14 2014-07-28 Novo Nordisk As Antibodies against human nkg2d and uses thereof
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
EP2262840A4 (en) 2008-03-03 2012-08-08 Dyax Corp Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
HRP20150965T1 (en) 2009-03-25 2015-11-06 Genentech, Inc. ANTI-FGR3 ANTIBODIES AND METHODS USED
EP2236517A1 (en) 2009-03-31 2010-10-06 Takara Bio, Inc. Anti-fibronectin fragment monoclonal antibody
US20110120350A1 (en) 2009-05-21 2011-05-26 Debrouse Daniel R Alginate-based building materials
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
AU2010288469A1 (en) 2009-08-31 2012-03-01 Roche Glycart Ag Affinity-matured humanized anti CEA monoclonal antibodies
UY32914A (en) 2009-10-02 2011-04-29 Sanofi Aventis ANTIBODIES SPECIFICALLY USED TO THE EPHA2 RECEIVER
JP5660486B2 (en) 2010-02-12 2015-01-28 国立大学法人 鹿児島大学 Antibodies against mucin 1 (MUC1) protein and uses thereof
JP6055312B2 (en) 2010-03-10 2017-01-11 ゲンマブ エー／エス Monoclonal antibody against C-MET
CA2796180A1 (en) 2010-04-15 2011-10-20 Alper Biotech, Llc Monoclonal antibodies against her2 antigens, and uses therefor
WO2011134060A1 (en) 2010-04-27 2011-11-03 National Research Council Of Canada Anti-icam-1 single domain antibody and uses thereof
WO2011139375A1 (en) 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
MX2012013702A (en) 2010-05-26 2013-03-21 Univ Minnesota Single -chain variable fragment anti-cd133 antibodies and uses thereof.
JP6320753B2 (en) 2010-05-27 2018-05-09 ゲンマブ エー／エス Monoclonal antibody against HER2
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
RU2598711C2 (en) 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Anti-tumour antigen antibody and methods of application
BR112013001637A2 (en) 2010-07-22 2016-05-24 Glaxosmithkline Biolog Sa antigen-binding protein, nucleic acid molecule, expression vector, recombinant host cell, methods for producing antigen-binding protein, and for detecting mage-a3 and / or mage-a6 in formalin-fixed, paraffin-infiltrated human tissue .
EP2714742A1 (en) 2011-06-03 2014-04-09 CT Atlantic Ltd. Magea3 binding antibodies
JP6220333B2 (en) 2011-07-15 2017-10-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 Antifolate receptor alpha antibodies and uses thereof
EP2548891A1 (en) 2011-07-18 2013-01-23 Universiteit Maastricht Human monoclonal antibody against the gamma subunit of the acetylcholine receptor for use in the treatment of rhabdomyosarcoma.
US9428577B2 (en) 2012-11-09 2016-08-30 Pfizer Inc. Platelet-derived growth factor B specific antibodies and compositions and uses thereof
SMT201800624T1 (en) 2012-11-21 2019-01-11 Janssen Biotech Inc Bispecific egfr/c-met antibodies
JP6224619B2 (en) 2012-12-07 2017-11-01 協和発酵キリン株式会社 Anti-FOLR1 antibody
CN117843785A (en) 2013-02-07 2024-04-09 Csl有限公司 IL-11R binding protein and its application
WO2014138449A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
HUE054057T2 (en) 2013-08-07 2021-08-30 Affimed Gmbh Antibody binding sites specific for egfrviii
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
WO2015173249A1 (en) 2014-05-14 2015-11-19 F. Hoffmann-La Roche Ag Her1 antigen binding proteins binding to the beta-hairpin of her1
KR102614642B1 (en) 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 Human monoclonal antibodies to ganglioside gd2
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
US10711068B2 (en) 2015-03-26 2020-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD133 monoclonal antibodies and related compositions and methods
EP4019552A1 (en) 2015-06-10 2022-06-29 National Research Council of Canada Carbonic anhydrase ix-specific antibodies and uses thereof
EP3313873A4 (en) 2015-06-24 2019-04-24 Eureka Therapeutics, Inc. CONSTRUCTS TARGETING NY-ESO-1 / MHC PEPTIDE COMPLEXES AND USES THEREOF
US20180057580A1 (en) 2016-08-29 2018-03-01 Regeneron Pharmaceuticals, Inc. Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension
SMT202300308T1 (en) 2016-09-23 2023-11-13 Regeneron Pharma Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
WO2018069871A2 (en) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CN107446050A (en) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 The compound and method of Trop2 positive diseases treatment
AU2018336017B2 (en) 2017-09-21 2021-06-24 Tigatx, Inc. Anti-GD2 antibody for the treatment of neuroblastoma
EP3625263B8 (en) 2017-10-27 2025-05-28 New York University Anti-galectin-9 antibodies and uses thereof
AR114001A1 (en) 2017-12-21 2020-07-08 Hoffmann La Roche ANTIBODIES THAT JOIN HLA-A2 / WT1
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
KR102584675B1 (en) 2018-05-23 2023-10-05 화이자 인코포레이티드 Antibodies specific for GUCY2c and their uses
CN118754985A (en) 2018-06-29 2024-10-11 爱必泰生物有限公司 Anti-L1CAM antibodies and uses thereof
AR114541A1 (en) 2018-08-03 2020-09-16 Amgen Res Munich Gmbh ANTIBODY CONSTRUCTS FOR CLDN18.2 AND CD3
EP3893930A4 (en) 2018-10-15 2022-08-24 Board of Regents, The University of Texas System MONOCLONAL ANTIBODIES AGAINST HUMAN DICKKOPF3 AND THEIR USES
CN109762067B (en) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 Antibodies that bind human Claudin18.2 and uses thereof
WO2020168059A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof

Also Published As

Publication number Publication date
CN121399157A (en) 2026-01-23
WO2024258870A8 (en) 2025-12-11
IL325097A (en) 2026-02-01
AR132931A1 (en) 2025-08-13
WO2024258870A2 (en) 2024-12-19
TW202506733A (en) 2025-02-16
AU2024305352A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
EA202190986A1 (en) HUMANIZED ANTIBODIES TO c-Kit
CL2021001790A1 (en) Non-trace linkers, protein conjugates thereof and compositions thereof
CO2021009693A2 (en) Anti-il2 gamma receptor antigen-binding proteins
MX2020010144A (en) Subcutaneous dosing of anti-cd38 antibodies.
CL2020000810A1 (en) Fusion proteins comprising enzyme replacement therapy enzymes.
EA202091887A1 (en) COMBINED CANCER THERAPY USING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
EA202091672A1 (en) STEROIDS AND THEIR ANTIBODY-CONJUGATES
UY39715A (en) ANTI-IL-2R AGONIST ANTIBODIES AND METHODS OF USE
MX2021014952A (en) SPECIFIC BINDING MOLECULE FOR CD73 AND USE OF THE BINDING MOLECULE.
MX2021004779A (en) Novel cd47 antibodies and methods of using same.
UY38748A (en) HEAVY-CHAIN MULTI-SPECIFIC ANTIBODIES JOINING CD22 AND CD3
AR075939A1 (en) ANTI-FGFR3 ANTIBODIES (FIBROBLAST GROWTH FACTOR RECEIVER) AND METHODS THAT USE THEM
MX2017011534A (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonsits.
MX2021008267A (en) ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES.
MX2020012273A (en) Protein binding nkg2d, cd16 and a fibroblast activation protein.
EA202090387A1 (en) PROTEINS BINDING NKG2D, CD16 AND FLT3
MX2020007406A (en) PD-L1 ANTIBODY, ANTIGEN-BINDING FRAGMENT OF THE SAME AND PHARMACEUTICAL USE OF THE SAME.
MX388786B (en) NMDA SPIRO-LACTAM MODULATORS AND METHODS OF USING THEM.
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
PH12021551494A1 (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
CL2022003715A1 (en) Tubulysins and protein-tubulysin conjugates
PE20211196A1 (en) METHODS TO TREAT IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNOSUPPRESSION
MX2020011529A (en) A METHOD TO OPTIMIZE THE EXPRESSION OF ANTIBODIES.
CL2023001140A1 (en) Anti-pd-l1 antibody formulations
BR112022012205A2 (en) ACTIVE COMPOUNDS FOR NUCLEAR RECEPTORS